SenoGuard Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Crowdfunding
  • (Announced)

  • Latest Deal Amount
  • $56.4K

  • Investors
  • 2

SenoGuard General Information

Description

Developer of radiation-free cancer treatment designed to treat patients suffering from breast cancer. The company has developed a new form of accommodative balloon cryoablation that provides recurrence protection with minimal to no side effects and at a fraction of the cost, enabling doctors to avoid problems associated with radiation therapy including multiple visits, possible cardiovascular complications, and cosmetic disfigurement.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 221 Main Street Box 351
  • Seal Beach, CA 90740
  • United States
Primary Industry
Biotechnology
Corporate Office
  • 221 Main Street Box 351
  • Seal Beach, CA 90740
  • United States

SenoGuard Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SenoGuard Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Equity Crowdfunding 31-Mar-2025 $56.4K Announced Generating Revenue
3. Accelerator/Incubator 12-Dec-2025 Completed Generating Revenue
2. Grant 01-Dec-2024 $1000K Completed Generating Revenue
1. Grant 15-Jan-2023 $256K Completed Generating Revenue
To view SenoGuard’s complete valuation and funding history, request access »

SenoGuard Patents

SenoGuard Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240148424-A1 Apparatus and method for marginal ablation in tissue cavity Pending 26-Feb-2021
WO-2022183117-A1 Apparatus and method for marginal ablation in tissue cavity Inactive 26-Feb-2021
US-20260263136-A1 Cryoablation system and method for treating breast tumor excision cavity margins with adaptive contact, tissue compression, and controlled cryogenic temperature delivery Pending 26-Feb-2021
US-20210153920-A1 Apparatus and method for ablation of soft tissue surrounding a breast cavity following lumpectomy Inactive 22-Nov-2019 A61B18/02

SenoGuard Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SenoGuard Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Octane (California) Accelerator/Incubator
US National Science Foundation Accelerator/Incubator
To view SenoGuard’s complete investors history, request access »

SenoGuard FAQs

  • When was SenoGuard founded?

    SenoGuard was founded in 2019.

  • Where is SenoGuard headquartered?

    SenoGuard is headquartered in Seal Beach, CA.

  • What is the size of SenoGuard?

    SenoGuard has 4 total employees.

  • What industry is SenoGuard in?

    SenoGuard’s primary industry is Biotechnology.

  • Is SenoGuard a private or public company?

    SenoGuard is a Private company.

  • What is SenoGuard’s current revenue?

    The current revenue for SenoGuard is .

  • Who are SenoGuard’s investors?

    Octane (California) and US National Science Foundation have invested in SenoGuard.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process